Dexamethasone in the treatment of COVID-19: Implementation and management of supply for treatment in hospitals
Early data from the RECOVERY trial found dexamethasone to have a clear clinical benefit in COVID-19 patients requiring oxygen or ventilation. This communication recommends clinicians consider using dexamethasone 6mg daily for 10 days, and that local policies are implemented.
Source:
Department of Health and Social Care
SPS commentary:
It is highlighted that dexamethasone was not used in pregnant women in the RECOVERY trial, and prednisolone 40 mg administered by mouth could be considered for pregnant and breastfeeding women.